Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped down before the market opened on Tuesday . The stock had previously closed at $6.51, but opened at $6.04. Inventiva shares last traded at $6.0510, with a volume of 105,328 shares changing hands.

Analysts Set New Price Targets

Several analysts have recently issued reports on IVA shares. Guggenheim decreased their target price on shares of Inventiva from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Inventiva in a research report on Tuesday, September 30th. UBS Group initiated coverage on Inventiva in a research note on Wednesday, January 7th. They set a “buy” rating and a $12.00 price target on the stock. HC Wainwright upped their price objective on Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Finally, Wall Street Zen upgraded Inventiva to a “hold” rating in a research note on Saturday, October 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $16.00.

Inventiva Stock Up 7.3%

The firm’s fifty day moving average is $4.73 and its 200 day moving average is $4.66.

Institutional Investors Weigh In On Inventiva

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock valued at $50,000 after purchasing an additional 5,843 shares in the last quarter. Creative Planning acquired a new position in Inventiva during the 2nd quarter worth approximately $32,000. Millennium Management LLC purchased a new stake in shares of Inventiva in the 3rd quarter valued at approximately $649,000. Finally, NewEdge Advisors LLC acquired a new stake in shares of Inventiva in the 3rd quarter valued at $116,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.